

**PHS PUBLIC ACCESS**

Author manuscript

Cell. Author manuscript; available in PMC 2016 June 18.

Published in final edited form as:

Cell. 2015 June 18; 161(7): 1553–1565. doi:10.1016/j.cell.2015.04.054.


Enhancing hematopoietic stem cell transplantation efficacy by mitigating oxygen shock**Charlie R. Mantel^{1,10}, Heather A. O'Leary^{1,10}, Brahmananda R. Chitteti², XinXin Huang¹, Scott Cooper¹, Giao Hangoc¹, Nickolay Brustovetsky³, Edward F. Srouf^{1,2,4}, Man-Ryul Lee^{1,7}, Steve Messina-Graham¹, David M. Haas⁵, Nadia Falah⁵, Reuben Kapur^{1,4,6}, Louis M. Pelus¹, Nabeel Bardeesy⁸, Julien Fitamant⁸, Mircea Ivan^{1,2}, Kye-Seong Kim⁹, and Hal E. Broxmeyer^{1,*}**¹Department of Microbiology/Immunology, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA²Department of Medicine (Hematology/Oncology), Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA³Department of Pharmacology and Toxicology, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA⁴Department of Pediatrics, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA⁵Department of Obstetrics and Gynecology, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA⁶Biochemistry/Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana, USA⁷Soonchunhyang Institute of Medi-bio Science, Chungcheongnam-do, Korea⁸Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA⁹Hanyang University, Seoul, Korea**Summary**

Hematopoietic stem cells (HSCs) reside in hypoxic niches within bone marrow and cord blood. Yet, essentially all HSC studies have been performed with cells isolated and processed in non-physiologic ambient air. By collecting and manipulating bone marrow and cord blood in native conditions of hypoxia, we demonstrate that brief exposure to ambient oxygen decreases recovery

*Correspondence to: hbroxmey@iupui.edu.¹⁰These authors contributed equally to this work.**Author Contributions:** CRM, HAO, HEB, co-wrote the paper, provided concepts, performed experiments and data analysis. BRC, X-XH, SC, GH, EFS, M-RL, SM-G, helped with experimental designs and performed experiments. DMH, NF, NB, RK, LMP, MI, NBr, NBa, JF, K-SK provided critical materials, knowledge on their use, and concepts. All authors reviewed the manuscript.**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

of long-term repopulating HSCs and increases progenitor cells, a phenomenon we term Extra Physiologic Oxygen Shock/Stress (EPOSS). Thus, true numbers of HSCs in the bone marrow and cord blood are routinely underestimated. We linked ROS production and induction of the mitochondrial permeability transition pore (MPTP) via cyclophilin D and p53 as mechanisms of EPOSS. MPTP inhibitor Cyclosporine A protects mouse bone marrow and human cord blood HSCs from EPOSS during collection in air, resulting in increased recovery of transplantable HSCs. Mitigating EPOSS during cell collection and processing by pharmacological means may be clinically advantageous for transplantation.

Abstract



Introduction

HSCs give rise to all the blood forming elements and their presence in bone marrow (BM), mobilized peripheral blood, and cord blood (CB) has allowed their harvesting for treatment of malignant and non-malignant disorders. However, the rarity of HSCs, particularly in cord blood grafts, can be a limitation of hematopoietic cell transplantation (Ballen et al, 2013). Uncovering mechanisms in HSC biology can identify new strategies to enhance numbers and function of HSCs and improve engraftment efficacy. While HSCs and hematopoietic progenitor cells (HPCs) proliferate better *in-vitro* in hypoxia than normoxia (Bradley et al., 1978; Broxmeyer et al., 1985; Danet et al., 2003; Lu and Broxmeyer, 1985; Smith and Broxmeyer, 1986), all HSC/HPC studies are performed after cell collection and processing in ambient air (~21% O₂) regardless of subsequent processing in hypoxia or air. The BM and CB environment where HSCs reside is extremely hypoxic compared to air (Morrison and Scadden, 2014, Nombela-Arrieta et al., 2013, Spencer et al., 2014). Thus, HSC collection in air is grossly hyperoxic compared to the BM microenvironment.

Stem cells rely heavily on glycolysis instead of mitochondrial respiration for bioenergetic demands (Xu et al., 2013). Mouse long term repopulating (LT)-HSCs harbor significant

numbers of mitochondria that appear to be inactive or “nascent”, and poised for rapid activation (Mantel et al., 2010). This is associated with initial differentiation of quiescent LT-HSCs into “activated” HSCs and short-term repopulating (ST)-HSCs. In mice, this is linked to lack of CD34 expression, and increased CD150 expression (Anjos-Afonso et al., 2013; Doulatov, et. al., 2012; Ema et al., 2007; Mantel et al., 2010), and is also thought to involve ROS (Jang and Sharkis, 2007; Lewandowski et al., 2010), a normal by-product of respiration that promotes HSC differentiation (Broxmeyer and Mantel, 2012; Ito et al., 2004; 2006; Tothova and Gilliland, 2009; Yalcin et al., 2008). We recently linked mitochondrial respiratory dysfunction and ROS overproduction to depletion of LT-HSCs, effects partially rescued by the ROS scavenger, N- acetyl-cysteine (Mantel et al., 2012). Therefore, we hypothesized that suppressing ROS during HSC collection and processing in a more physiological low O₂ environment (hypoxia), might offer protection from mitochondrial dysfunction and result in increased HSC recovery.

Here we provide a rigorous analysis of how brief exposure of HSCs to air affects the efficiency of HSC collection and transplantation success, and describe the molecular mechanisms underlying it. We show that exposure to air during collection limits the yield of HSCs from BM and CB, and name this phenomenon “Extra Physiologic Oxygen Shock/ Stress” (EPOSS). EPOSS effects are mediated by ROS production linked to cyclophilin D (CypD), p53, and the mitochondrial permeability transition pore (MPTP). Importantly, inhibition of EPOSS using Cyclosporine A enhances the yield of HSCs and the efficacy of their transplantation. This phenomenon, suggesting that greater numbers of HSCs reside in hematopoietic tissues and that their *in vivo* metabolism is different from the one *ex-vivo* in air raises questions regarding *in-vivo* relevance of studies of HSC and HPC collected in air. Moreover, hematopoietic cell transplantation, especially where donor HSCs are limited, may be improved if EPOSS is prevented or attenuated by collection and processing of cells under hypoxia, or alternatively in air in the presence of Cyclosporine A, or through other pharmacological targeting of the MPTP.

Results

Effects of “Hypoxic-Harvest”

To limit ROS production and HSC differentiation, mouse BM was collected/processed under constant hypoxia (3% O₂), and compared to air-harvested BM: either, one femur was harvested inside a hypoxic chamber and the other in air, or BM was collected in the chamber and aliquots exposed to ambient air or left in the chamber for processing. Figure S1A shows the hypoxic chamber used for these studies. Most importantly, all reagents and supplies were equilibrated to hypoxia (3% O₂) for at least 18 hrs prior to use.

Up to five-fold greater numbers of phenotypically defined mouse BM LT-HSCs (Lineage⁻Sca1⁺c-kit⁺(LSK)CD48⁻CD34⁻) were recovered by harvesting and maintaining cells in constant hypoxia (3% O₂) compared to air (Figure 1A). Similar increases were noted when cells were collected and processed in hypoxia (H→H), compared to cells collected in hypoxia then placed in air (H→A) for 60 minutes prior to assessment (Figure 1B), an effect rapidly lost, if cells were exposed to air for as short as 30 minutes (Figure 1C). This pattern was also observed if CD150 (Oguro, et al., 2013) was used to phenotypically delineate LT-

HSCs instead of CD34 (CD150⁺CD48⁻CD41⁻LSK; Figure S1B). As the CD48⁻CD41⁻LSK population displays less CD34 on their surface, they increase CD150 expression (Figure 1D). This verifies that phenotypically-defined mouse BM LT-HSCs are recovered in greater numbers when harvested in hypoxia and prevented from any exposure to air, regardless of phenotypic markers utilized. ROS levels were increased in LT-HSCs and CD48⁻ LSK cells (containing HSCs and HPCs) harvested in air compared to hypoxia (Figure 1E). Elevated mitochondrial activities (Figure 1Fi) and increased numbers of primitive cells with hyperpolarized mitochondria (Figure 1Fii) were found in air harvested BM. Thus, decreased LT-HSCs correlated with augmented mitochondrial activity in air-exposed BM cells. Numbers of ST-HSCs (CD34⁺CD48⁻LSK cells) and multi-potent progenitors (MPPs; CD48⁻Lin⁻c-kit⁺Sca1⁻) were increased after air exposure (Figure 1G and Figure S1C) suggesting rapid differentiation of LT-HSC to ST-HSC and HPC in air. Hypoxic-harvested BM contained reduced numbers and cell cycling of immature subsets of multi-cytokine stimulated HPCs (Figure 1H; assessed by colony assays), consistent with reduced ROS-mediated cytokine-induced signaling and differentiation (Sattler, et al., 1999). Thus, true numbers/frequency of LT-HSCs have previously been greatly underestimated and numbers and cycling status of HPCs overestimated in mouse BM as they exist in their native low [O₂] environment. Collection/processing of mouse BM at 5% O₂ did not increase numbers of HSCs as did 3% O₂ (Figure S1D).

Human CB is also hypoxic compared to ambient air (Sjostedt et al., 1960). Thus, human CB was collected with syringes designed to greatly minimize exposure of CB to air (Experimental Procedures) and was typically transferred within 10 minutes into the hypoxic chamber for further processing. Human CB-derived HSCs, identified as Lin⁻CD34⁺CD38⁻CD45RA⁻CD90⁺CD49f⁺ (Notta et al., 2011; Doulatov et al., 2012), resulted in ~3-fold greater recovery compared to cells handled in air (Figure 1I), consistent with mouse BM hypoxic-harvests, suggesting exquisite sensitivity of HSCs to EPHOSS, and demonstrating that EPHOSS is not restricted to BM.

Since phenotype does not always recapitulate function, especially under stress (Broxmeyer et al., 2012), we assessed HSC function by competitive transplantation. Mouse BM was harvested, processed, and injected into mice in a hypoxic chamber, or cells were collected in hypoxia, exposed to air for >60 minutes before processing and transplantation in air. A custom mouse respiration device facilitated tail vein injection inside the hypoxic chamber (Figure S1E). Recipient mice were only briefly (<10 sec) exposed to low O₂. Competitor BM was collected in air and infused after the donor cells. Engraftment was significantly increased when donor BM was harvested, processed, and transplanted in low O₂, compared to BM harvested in hypoxia and then exposed to air (Figure 2Ai), consistent with increased numbers of functional HSCs being present in hypoxic-harvested BM. Low-level engraftment was seen with air-exposed donor cells, while engraftment of hypoxia-harvested, processed, and i.v.-injected donor BM cells resulted in quite significant enhancement in peripheral blood and BM chimerism in primary mice, as well as enhanced repopulation in secondary mice. Two other similar engraftment experiments were performed, including one with “air-only” harvest compared to “hypoxic-only” harvest. Chimerism of air-harvested donor cells was higher in the two latter experiments than that in Figure 2Ai even though similar donor to competitor numbers were used. Combined results of all three experiments demonstrated

Author Manuscript
Author Manuscript
Author Manuscript

significant enhancement for hypoxia-harvested, processed, and injected BM donor cells (Figure 2Aii and Figure S2A (Competitive repopulation units (RUs), as calculated by the method of Harrison and Astle, 1997)). Limiting dilution analysis at month 3 for PB and month 7/8 for BM performed for 2 of the experiments shown in Figure 2Aii for hypoxia vs. air harvested cells demonstrated increased Competitive Repopulating Units (CRUs) respectively of 2.5 and 2.4 fold (Figure 2Aiii; Figure S2B). There was no significant difference in lymphoid and myeloid end stage cell graft contribution in air vs. hypoxia harvested, processed, and injected cells in the engrafted mice (Figure S2C). Enhanced engraftment of hypoxic-harvested/processed cells was not due to homing (Figure 2B; “homed” LSK cells were collected in hypoxia and then analyzed either in hypoxia or 1 hour after placement in air with no differences noted for “homed” cells either way). Enhanced engraftment did not correlate with enhanced CXCR4 expression, which was decreased on hypoxic- compared to air-harvested LT-HSCs (Fig 2C). Apoptosis, assessed by intracellular active caspase-3 levels, was not different when hypoxic-harvested BM was exposed to air for 60 min (Figure 2D and Figure S2D and E). So, cell death could not explain loss of HSC when BM was exposed to air. The picture emerging from our studies is that harvesting donor BM in air, or even brief exposure to air (i.e. in response to EPHOSS), has a rapid, deleterious effect on numbers and repopulating potential of HSC.

Mechanisms of EPHOSS were assessed for biologic insights, and alternative means of collecting cells to mimic effects seen in low O₂ for practical applicability. Physiological damage from heart attack, stroke, and other ischemic events occurs upon restoration of circulation and tissue “re-oxygenation”. So-called ischemia-reperfusion damage is believed initiated by a burst of oxygen radicals rapidly produced by mitochondria (Kalogeris et al., 2012; Perrelli, 2011), with some similarity to air BM harvest. Induction of the MPTP is implicated in mechanisms of ischemia-reperfusion damage (Griffiths and Halestrap, 1995; Kim et al., 2003; Lim et al., 2010). This may be similar to what HSCs experience upon harvest in ambient air, with induction of the MPTP via oxidative stress. While oxidative stress favors MPTP induction resulting in mitochondrial swelling and OXPHOS uncoupling (Halestrap and Davidson, 1990) leading to apoptosis and necrosis (Vaseva et al., 2012), MPTP opening can also be intermittent/transient and function in a regulatory capacity conducive to regulation of differentiation of stem cells. We hypothesized that the MPTP is involved in EPHOSS because of similarities to ischemia-reperfusion.

MPTP is key to EPHOSS mechanism

Author Manuscript

A key regulatory component of the MPTP is peptidyl-prolyl *cis-trans* isomerase or Cyclophilin D (CypD; also called cyclophilin F) which is encoded by the *Ppif* gene and regulates MPTP induction (Tanveer et al. 1996). Oxidative stress facilitates recruitment of mitochondrial CypD to the inner membrane and promotes MPTP induction (Connern and Halestrap, 1994). Cyclosporin A (CSA) a small molecule inhibitor of CypD binds CypD, antagonizes MPTP induction (Halestrap and Davidson, 1990; McGuinness et al., 1990; Nicolli et al., 1996), and prevents ischemia-re-oxygenation damage (Hausenloy et al., 2012). Federal Drug Administration approved CSA is being tested for treatment of heart attack and stroke, and is an immunosuppressant in graft vs. host disease (GVHD) for HCT (Junghanss et al., 2012; Kikuchi et al., 2012). To test MPTP involvement in EPHOSS mechanisms, and

for possible protective effects of MPTP inhibition, BM was harvested in air with CSA. Harvest of cells with CSA resulted in ~4-fold significant increase in recovery of LT-HSC numbers (Figure 3A-C). LT-HSCs declined rapidly when BM was harvested in air without CSA (Figure 3Ciii), consistent with kinetics in hypoxic/air-harvest experiments (Figure 1). CSA-harvest also suppressed multi-cytokine induced proliferation of CFU-GM (Figure 3D), implicating CypD and the MPTP in cytokine signaling/function. Delaying addition of CSA for 15 min. while collecting mouse BM in air did not rescue the EPHOSS effect, and resulted in decreased numbers of LT-HSC, and increased numbers of ST-HSC and MPP, along with increased ROS in the 3 cell types (Figure S3).

Non MPTP-related immunosuppressive CSA effects are mediated by inhibition of the calcineurin pathway (Liu, et al., 1991). To determine if this pathway is involved in CSA protection against EPHOSS, BM was harvested in air with calcineurin inhibitor, FK506, which does not inhibit the MPTP and is used to address specificity of agents thought to affect the MPTP (Friberg et al., 1998). “FK506-harvest” did not protect LT-HSCs from EPHOSS (Figure 3E), confirming CSA protects LT-HSCs from EPHOSS via suppression of the MPTP. BM was also harvested in air in the presence of carboxyatractylate (CAT), an agent that binds to adenine nucleotide translocase, stabilizes it in the *c*-conformation, and favors MPTP opening (Halestrap and Brenner, 2003). “CAT-harvest” resulted in loss of LT-HSC recovery (Figure 3F), which was greater than that by air-harvest alone. ROS levels were reduced in LT-HSCs and HPCs when BM was harvested with CSA, but increased in presence of CAT (Figure 3G), further supporting MPTP opening mediated ROS generation in molecular mechanisms of EPHOSS. To determine if “CSA-harvest” protects functional HSCs from EPHOSS, we performed competitive repopulation experiments. BM harvested in the presence of CSA from donor mice that were pretreated with CSA had enhanced competitive engraftment as determined by donor cell chimerism (Figure 3Hi), CRUs from limiting dilution analysis (Figure 3Hii, Figure S4A), RUs calculated by the method of Harrison and Astle, 1997 (Figure S4B), and enhanced secondary repopulation (Figure 3Hi). Lymphoid and myeloid cell numbers of CSA vs. non-CSA collected, processed, and injected cells in the engrafted mice were similar (Figure S4C).

To assess potential clinical applicability, we performed engraftment studies of CSA (diluted in DMSO) vs. DMSO control collection and processing of human CB. In two separate experiments, there were increased numbers of human CD34⁺ cells and LT-HSCs and decreased MPP numbers (Figure 4A). There was enhanced engraftment in NSG mice of CSA collected and processed CB, as assessed by limiting dilution analysis for SCID Repopulating Cells (SRCs) (Figure 4Bi-4Biii; Figure S5Ai - Aiii), without significant differences in lymphoid and myeloid end stage cell graft contribution (Figure S5B). Data in Figure 3 and Figure 4A-C demonstrates that regulation of the MPTP by CypD is an important mechanism of EPHOSS, and suppression of CypD opening of the MPTP with CSA may have practical clinical value.

MPTP-cyclophilin D-p53 Axis is involved in EPHOSS

We reasoned that *CypD* gene deletion, which prevents MPTP induction (Baines et al., 2005; Baines, 2010; Kalogeris et al., 2012), might protect against EPHOSS. *CypD*^{-/-} mice are

protected against MPTP-dependent ischemia-reperfusion damage (Baines et al., 2005; Schinzel et al., 2005; Nakagawa et al., 2005). LT-HSC recovery was significantly increased (Figure 4Ci), and ROS levels in LT-HSC significantly reduced (Figure 4Cii) in *CypD*^{-/-} BM harvested in air. HPC numbers were fewer in *CypD*^{-/-} BM (Figure 4D) and colony formation of CFU-GM in response to stimulation by a different multi-cytokine combination was also inhibited (Figure 4E), analogous to results of CSA treatments (Figure 3D). This strongly implicates *CypD* and MPTP mediated ROS production in cytokine signaling/stimulation of HPC proliferation. Chimerism (Figure 4Fi) and limiting dilution analysis to calculate CRUs, along with analysis of lymphoid/myeloid engraftment (Figure 4Fii; Figure S5C-F) demonstrated increased engrafting capability of *CypD*^{-/-} BM HSC without changes in numbers of lymphoid and myeloid cells. The importance of the MPTP in EPHOSS is demonstrated in Figure 4C-F.

ROS can be produced by mitochondrial and non-mitochondrial sources. Mitochondrial ROS production in cells predominantly occurs in the electron transport chain and is therefore closely linked to respiratory activity, which in turn depends on coupling to ATP synthesis. We wondered if *CypD*^{-/-} cells may have any abnormalities in respiration and OXPHOS and if these abnormalities could clarify mechanisms behind lower ROS generation in *CypD*^{-/-} cells. We used a Seahorse XF96 flux analyzer to assess cell respiration. Because LT-HSCs are rare, we used a surrogate hematopoietic cell, a strategy used previously (Mantel, et al., 2012). Non-mitochondrial respiration in *CypD*^{-/-} cells was similar to that in WT cells and well coupled to ATP synthesis as determined by inhibition of respiration by rotenone and sensitivity to oligomycin A, respectively (Figure S6). Basal respiration and maximal respiratory capacity was higher in *CypD*^{-/-} cells compared to WT cells, suggesting a potential mechanistic link between mitochondrial electron transport chain/respiration regulation and reduced ROS generation in hematopoietic cells in the absence of *CypD*.

p53 deletion is one of few gene deletions resulting in increases in HSC numbers and engraftment (Copley et al., 2012; Nii et al., 2012; Rossi et al., 2012). Recent findings indicate that *p53* may facilitate MPTP opening (Vaseva et al, 2012; Zhen et al., 2014). We hypothesized that *p53*^{-/-} might protect HSCs from EPHOSS by suppressing MPTP opening. We also considered if resistance to EPHOSS could have had a role in interpretation of results leading to the idea that *p53*^{-/-} BM contains increased HSCs. We now report that expected increases in HSC numbers in *p53*^{-/-} mouse BM are not apparent with BM harvested and assayed in 3% O₂, and is only apparent when BM is harvested and exposed to air (Figure 5A), suggesting a role for *p53* in HSC biology directly related to EPHOSS. This may influence current concepts about effects of *p53*^{-/-} on HSC biology *in-vivo*. We also noted decreased numbers and cell cycle of *p53*^{-/-} HPCs compared to WT if BM was harvested in low [O₂] and exposed to air (Figure 5B). However, if *p53*^{-/-} BM was harvested and cultured in low [O₂], there were increased numbers and cycling of progenitors compared to WT BM harvested and cultured the same way. Therefore, analogous to effects of hypoxic harvest of LT-HSCs from *p53*^{-/-} mice (Figure 5A), interpretation of effects of *p53*^{-/-} on functional HPC is highly dependent on whether BM was exposed to air, and suggests involvement of a *p53*-*CypD*-MPTP axis in EPHOSS mechanisms.

HIF-1 α , miR210, and EPHOSS

Most tissues in the human body reside in an O₂ environment considerably lower than that of ambient air. If cells/tissues like HSCs that normally reside in low O₂ conditions are collected and studied in ambient air, this could lead to incomplete understanding of their biology/biochemistry unless EPHOSS is considered.

To gain additional support for this idea, we investigated two other gene deletions models connected to the biology of hypoxia: the hypoxamir miR210 and HIF-1 α (Chan and Loscalzo, 2010; Devlin et al., 2011; Speth et al, 2014; Zhang et al., 2012). We wished to see if miR210 and HIF-1 α may be linked to EPHOSS, and to discern if we would detect differences in HSC and HPC numbers from these gene knockout mice compared to control mice when cells are collected in air vs. 3% O₂. Deletion of either gene suppressed hypoxic-harvest-enhanced recovery of LT-HSCs (Figure 5Ci and ii) with amelioration of decreased recovery of ST-HSCs and MPPs by hypoxic harvest compared to WT controls. Hypoxic harvest of cells from control mice resulted, as already shown in Figure 1H, in decreased functional HPCs from WT BM, an effect not seen in either *miR210*^{-/-} or *hif-1 α* ^{-/-} (Figure 5Di and ii). These data implicate *miR210* and *hif-1 α* in EPHOSS, but don't yet elucidate mechanistic links. The experimental results obtained were dependent on BM harvest conditions, similar to what was observed for the *CypD*^{-/-} and *p53*^{-/-} models.

Discussion

Our studies illuminate several seminal concepts. First, HSCs from mouse BM or human CB can be collected in greater numbers than previously recognized, and which have been until now significantly underestimated by routine harvesting and processing in air. This information could lead to improvements especially for CB-hematopoietic cell transplantation where low cell numbers collected in single units create clinical limitations (Ballen et al., 2013). Moreover, there is a potential for rapid clinical translation because CSA, which protects HSCs from EPHOSS during air-harvest via inhibition of the MPTP, is already used clinically as an immunosuppressant.

On a more fundamental level, our study also provides insight into the cellular effects of oxygen exposure, linking hypoxia, CypD, and the MPTP in cytokine signaling/functions, and suggesting new types of “mitochondria-centric” cytokine signal transduction pathways that precisely link proliferation and differentiation signals to cellular bioenergetics, metabolism, and programmed cell death via the MPTP. Moreover, using four gene deletion mouse models we highlight how interpretation of experimental results of gene deletion models can be influenced by EPHOSS. While CypD or p53 deletion have an EPHOSS-protective effect, miR210 and hif-1 α deletion abrogates protection afforded by hypoxic harvest. This reveals a specificity of EPHOSS requirements relative to several different factors that will have to be further evaluated.

Because different adult stem cells naturally exist in hypoxic niches, EPHOSS may be relevant to other stem cells routinely harvested in air. Embryonic stem cells in the inner cell mass of blastocysts, as well as cancer stem cells, all reside in hypoxic environments (Brown and Giaccia, 1998; Hill et al., 2009; Millman et al., 2009; Mohyeldin et al., 2010) and ROS

is important in growth, differentiation, and regulation of these cells (Tothova and Gilliland, 2009). Human ESCs derived from 8-cell embryos thawed from liquid nitrogen under 5% O₂ better maintained pluripotency, although in those studies embryos were originally harvested in air (Lengner et al., 2010). Another important point to consider here is that there is much information about the metabolic regulation of HSCs (Suda et al., 2011), and some may now need to be rigorously re-evaluated in context of EPHOSS. One example of issues arising from our findings is that metabolic profiling for development of “personal” therapeutic strategies to target cancer stem cells (Hsu and Sabatini, 2008; Kamleh et al., 2011; Wood et al., 2014) may not accurately represent the metabolism of these cells as they exist in their native hypoxic environments because they are harvested and studied in air. It is also possible, and indeed highly likely, that EPHOSS will influence the metabolism and differentiation of other cell types including lymphocytes, monocytes/macrophages, neutrophils, fibroblasts, and others, since these cells also reside in hypoxic environments.

Another point deserving exploration is detrimental effects of aging on HSCs and other tissue-specific stem cells (Chambers et al., 2007; Ergen and Goodell, 2010; Mantel and Broxmeyer, 2008; Mantel et al., 2011; Sudo et al., 2000). ROS is considered a major driver in aging (Finkel et al., 2007; Harper et al., 2004), and it is possible that stem cells from aged animals are more vulnerable to EPHOSS-linked ROS production when studied in air. Thus, cells collected from aged animals or humans using efforts that mitigate EPHOSS effects may have greater therapeutic potential.

In summary, we believe that knowledge of EPHOSS will have widespread ramifications for studies of cellular metabolism and function in many stem/progenitor and other cell systems.

Experimental Procedures

Animals

Mice used for most BM harvests and for transplantation were female C57BL6/J and 4-6 weeks of age, while mice for the other experiments were males and females with ages ranging from 6-20 weeks of age. Mice were age and sex-matched. In some cases, controls were littermates. Constitutive *CypD*^{-/-} (*Ppif*^{-/-}) mice (B6; 129-Ppif^{tm/JMOL/J}) were purchased from Jackson Laboratory (Bar Harbor, ME). We verified knock-out of *CypD* in hematopoietic cells by Western blotting (Figure S7A). *p53*^{-/-} mice on B1/6 background were as reported (Jacks et al., 1994; Vemula et al., 2012), and knock-out verified by PCR (Figure S7B). Tamoxifen-induced conditional *hif1α*^{-/-} mice were as reported where ERT-2 Cre + Flox ± and their ERT-2 Cre-Flox +/+ littermate controls both received Tamoxifen and knock-out confirmed by PCR (Speth et al., 2014). *miR210*^{-/-} mice were developed in the laboratory of Nabeel Bardeesy (Massachusetts General Hospital, Boston, MA) and successful KO determined by PCR (Figure S7C). See Extended Experimental Procedures. B1/6, B6BoyJ and F1 mice were from our Animal Cores.

Flow cytometry

This was done using an LSRII cytometer or FACS Caliber (Becton Dickinson, San Diego, CA) and chromophore-conjugated antibodies used for mouse BM cell phenotyping (Mantel

et al., 2010; 2012). See also Figure S1C. Antibodies used for human phenotyping (Notta et al., 2011) were anti-lineage cocktail, CD34, CD38, CD45RA, CD90, and CD49f (BD Biosciences). For mitochondrial mass, membrane potential, and ROS analysis (Mantel et al., 2010; 2012), we used Mitotracker Green FM, JC-1, and Mitotracker Orange CMTMRos respectively (Molecular Probes, Life Technologies; Grand Island, NY). CXCR4 antibodies were purchased from BD Biosciences. Phenotyping for mouse transplant chimerism/ engraftment analysis was as noted (Mantel et al., 2012; Broxmeyer et al., 2012). Flow cytometric analysis of apoptosis was assessed by activated caspase-3 (Mantel, et al., 2007).

Cell Harvests

Hypoxic BM harvest was done in a custom configured, temperature, humidity, O₂, CO₂ controlled glove box (Figure S1; Hypoxic Chamber; Coy, Inc., Green Lakes, Michigan) routinely maintained at 3% oxygen, 5% CO₂, and nitrogen balance. After sacrifice, animals were immediately passed into the chamber through a gassed air lock where femurs were obtained and flushed. All solutions, media, reagents, and especially all plastic ware and pipet tips, sterile gauze, and anything that could come into contact with either the femur or the flushed BM cells was pre-equilibrated in the hypoxic chamber for at least 18 hours prior to their use. Subsequent procedures such as surface marker staining and fixation and colony assay procedures were done inside the chamber (Extended Experimental Procedures). CSA-harvests (50ug/ml) were used for BM collection and also injected i.p. at 100ug into mice 18-24 hours before BM harvest, although subsequent experiments did not demonstrate differences in CSA collection of HSCs whether or not mice were injected with CSA before collection of BM cells in CSA. FK506 and CAT were used at 50µg/ml. CSA, FK506, and CAT were purchased from Sigma Chem. Co., St. Louis, MO.

Human CB was harvested as reported (Broxmeyer et al., 2006), except airtight arterial blood gas-syringes (McKesson Medical-Surgical, Richmond, VA) equilibrated in the hypoxic chamber were used such that exposure to air was greatly minimized. Syringes were transported from delivery room to laboratory in airtight plastic containers, and placed back into the hypoxic chamber often within 10 minutes of collection. A portion of hypoxic-harvested CB was exposed to air. Centrifugation of hypoxic harvested BM and CB was done inside the hypoxic chamber or airtight tubes in tabletop centrifuges.

Collection of CB was performed within 5 minutes of placental delivery. Through a single venipuncture, 15-25ml of blood was harvested into a 60cc syringe containing 20ml of either phosphate buffered saline (PBS) with heparin (H)(Sigma #H3393) at 1000 units/ml and CSA(Sigma #P500092) at 50ug/ml or PBS/H with DMSO (D) at equivalent volume of CSA. Each collection was immediately added respectively to 50ml of either PBS/H/CSA or DPBS/H/D in a sterile container and mixed thoroughly. Blood was further processed for mononuclear cells and enriched for CD34 cells using standard protocols for Ficoll separation and micro-bead isolation with all solutions respectively containing either CSA at 50ug/ml or equivalent volume of DMSO.

Transplantation

Recipient F1 mice were continuously fed uniprim feed and irradiated with one dose of 950cGy 24 hours prior to transplantation with engraftment (Broxmeyer et al., 2012) detailed in Figure legends. Homing is described in Extended Experimental Procedures.

Limiting dilution analysis (LDA)

The frequency of mouse CRUs and human SRCs were analyzed by LDA as previously reported (Antonchuk, et. al. 2002; Boitano, et. al., 2010). For mouse experiments, increasing doses of C57BL/6 BM cells (CD45.2⁺) with B6 BoyJ (CD45.1⁺) competitor cells were transplanted into lethally irradiated (950 cGy) F1 (CD45.2/CD45.1⁺) recipient mice. For human experiments, increasing doses of CD34⁺ cells were infused into sublethally irradiated (300 cGy) NSG mice. For each LDA experiment, mice were transplanted with either of 3 cell concentrations with the second being half of the first and the third being half of the second. Numbers of mice for each dilution are given in Figure Legends. HSC frequency was calculated using L-Calc software (StemCell Technologies Inc.) and plotted using ELDA software (bioinf.wehi.edu.au/software/elda/). Poisson statistics was used to calculate the p value for all LDA analyses.

Colony Assays and Tritiated Thymidine Kill Assay

These were done as reported (Broxmeyer et al., 2012; Mantel et al., 2012). Colonies were scored after incubation at 5% O₂, 5% CO₂ to maximize detectable colony numbers.

Respirometry

Extracellular flux respirometry was done on mouse splenocytes as reported (Mantel, et al., 2012).

Statistics

Statistical analysis was done using a 2-tailed student *t*-test, or where indicated by ANOVA, or Mann-Whitney.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Research was supported by US Public Health Service Grants from NIH: R01 HL67384, R01 HL056416, R01 HL112669, and P30 DK090948 to HEB, the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (2012M3A9B4028738) and a grant of the Korea Health technology R&D Project, Ministry of Health & Welfare (A120262), Republic of Korea to K-S.K. HAO and SM-G were supported by NIH T32 training grant DK07519 to HEB. NBr was supported by NIH R01 NS078008. We thank P.L. Mantel for editorial assistance.

We would like to dedicate this paper to Dr. Donald Metcalf, a pioneer in the field of hematopoiesis, who recently passed away.

References

- Anjos-Afonso F, Currie E, Palmer HG, Foster KE, Taussig DC, Bonnet D. CD34(-) Cells at the Apex of the Human Hematopoietic Stem Cell Hierarchy Have Distinctive Cellular and Molecular Signatures. *Cell Stem Cell*. 2013; 13:161–174. [PubMed: 23910083]
- Antonchuk J, Sauvageau G, Humphries RK. HOXB4-induced expansion of adult hematopoietic stem cells ex vivo. *Cell*. 2002; 109:39–45. [PubMed: 11955445]
- Baines CP. The cardiac mitochondrion: nexus of stress. *Annu Rev Physiol*. 2010; 72:61–80. [PubMed: 20148667]
- Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA, Brunskill EW, Sayen MR, Gottlieb RA, Dorn GW, et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. *Nature*. 2005; 434:658–662. [PubMed: 15800627]
- Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. *Blood*. 2013; 122:491–498. [PubMed: 23673863]
- Boitano AE, Wang J, Romeo R, Bouchez LC, Parker AE, Sutton SE, Walker JR, Flaveny CA, Perdew GH, Denison MS, Schultz PG, Cooke MP. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. *Science*. 2010; 329:1345–1348. [PubMed: 20688981]
- Bradley TR, Hodgson GS, Rosendaal M. The effect of oxygen tension on haemopoietic and fibroblast cell proliferation in vitro. *J Cell Physiol*. 1978; 97:517–522. [PubMed: 730784]
- Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. *Cancer Res*. 1998; 58:1408–1416. [PubMed: 9537241]
- Broxmeyer HE, Mantel C. A ROSy future for metabolic regulation of HSC division. *Nature*. 2012; 18:1334–1336.
- Broxmeyer HE, Cooper S, Rubin BY, Taylor MW. The synergistic influence of human interferon-gamma and interferon-alpha on suppression of hematopoietic progenitor cells is additive with the enhanced sensitivity of these cells to inhibition by interferons at low oxygen tension in vitro. *J Immunol*. 1985; 135:2502–2506. [PubMed: 3928752]
- Broxmeyer HE, Hoggatt J, O'Leary HA, Mantel C, Chitteti BR, Cooper S, Messina-Graham S, Hangoc G, Farag S, Rohrabough SL, et al. Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis. *Nature Medicine*. 2012; 18:1786–1796.
- Broxmeyer HE, Srour E, Orschell C, Ingram DA, Cooper S, Plett PA, Mead LE, Yoder MC. Cord blood stem and progenitor cells. *Meth Enzymol*. 2006; 419:439–473. [PubMed: 17141066]
- Chambers SM, Shaw CA, Gatzka C, Fisk CJ, Donehower LA, Goodell MA. Aging Hematopoietic Stem Cells Decline in Function and Exhibit Epigenetic Dysregulation. *PLoS Biology*. 2007; 5:e201. [PubMed: 17676974]
- Chan SY, Loscalzo J. MicroRNA-210: a unique and pleiotropic hypoxamir. *Cell Cycle*. 2010; 9:1072–1083. [PubMed: 20237418]
- Connern CP, Halestrap AP. Recruitment of mitochondrial cyclophilin to the mitochondrial inner membrane under conditions of oxidative stress that enhance the opening of a calcium-sensitive non-specific channel. *Biochem J*. 1994; 302(Pt 2):321–324. [PubMed: 7522435]
- Copley MR, Beer PA, Eaves CJ. Hematopoietic stem cell heterogeneity takes center stage. *Cell Stem Cell*. 2012; 10:690–697. [PubMed: 22704509]
- Danet GH, Pan Y, Luongo JL, Bonnet DA, Simon MC. Expansion of human SCID-repopulating cells under hypoxic conditions. *J Clin Invest*. 2003; 112:126–135. [PubMed: 12840067]
- Devlin C, Greco S, Martelli F, Ivan M. miR-210: More than a silent player in hypoxia. *IUBMB Life*. 2011; 63:n/a–n/a.
- Doulatov S, Notta F, Laurenti E, Dick JE. Hematopoiesis: A Human Perspective. *Cell Stem Cell*. 2012; 10:120–136. [PubMed: 22305562]
- Ema H, Morita Y, Yamazaki S, Matsubara A, Seita J, Tadokoro Y, Kondo H, Takano H, Nakauchi H. Adult mouse hematopoietic stem cells: purification and single-cell assays. *Nature Protocols*. 2007; 1:2979–2987.

- Ergen AV, Goodell MA. Mechanisms of hematopoietic stem cell aging. *Exp Gerontol.* 2010; 45:286–290. [PubMed: 20034552]
- Finkel T, Serrano M, Blasco MA. The common biology of cancer and ageing. *Nature.* 2007; 448:767–774. [PubMed: 17700693]
- Friberg H, Ferrand-Drake M, Bengtsson F, Halestrap AP, Wieloch T. Cyclosporin A, but not FK 506, protects mitochondria and neurons against hypoglycemic damage and implicates the mitochondrial permeability transition in cell death. *J Neurosci.* 1998; 18:5151–5159. [PubMed: 9651198]
- Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. *Biochem J.* 1995; 307(Pt 1):93–98. [PubMed: 7717999]
- Halestrap AP, Brenner C. The adenine nucleotide translocase: a central component of the mitochondrial permeability transition pore and key player in cell death. *Curr Med Chem.* 2003; 10:1507–1525. [PubMed: 12871123]
- Halestrap AP, Davidson AM. Inhibition of Ca²⁺(+)-induced large-amplitude swelling of liver and heart mitochondria by cyclosporin is probably caused by the inhibitor binding to mitochondrial-matrix peptidyl-prolyl cis-trans isomerase and preventing it interacting with the adenine nucleotide translocase. *Biochem J.* 1990; 268:153–160. [PubMed: 2160810]
- Harper ME, Bevilacqua L, Hagopian K, Weindruch R, Ramsey JJ. Ageing, oxidative stress, and mitochondrial uncoupling. *Acta Physiol Scand.* 2004; 182:321–331. [PubMed: 15569093]
- Harrison DE, Astle CM. Short- and long-term multilineage repopulating hematopoietic stem cells in late fetal and newborn mice: models for human umbilical cord blood. *Blood.* 1997; 90:174–181. [PubMed: 9207451]
- Hausenloy DJ, Boston-Griffiths EA, Yellon DM. Cyclosporin A and cardioprotection: from investigative tool to therapeutic agent. *Br J Pharmacol.* 2012; 165:1235–1245. [PubMed: 21955136]
- Hill RP, Marie-Egyptienne DT, Hedley DW. Cancer stem cells, hypoxia and metastasis. *Semin Radiat Oncol.* 2009; 19:106–111. [PubMed: 19249648]
- Hsu PP, Sabatini DM. Cancer Cell Metabolism: Warburg and Beyond. *Cell.* 2008; 134:703–707. [PubMed: 18775299]
- Ito K, Hirao A, Arai F, Matsuoka S, Takubo K, Hamaguchi I, Nomiya K, Hosokawa K, Sakurada K, Nakagata N, et al. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. *Nat Cell Biol.* 2004; 431:997–1002.
- Ito K, Hirao A, Arai F, Takubo K, Matsuoka S, Miyamoto K, Ohmura M, Naka K, Hosokawa K, Ikeda Y, et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. *Nat Med.* 2006; 12:446–451. [PubMed: 16565722]
- Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA. Tumor spectrum analysis in p53-mutant mice. *Curr Biol.* 1994; 4:1–7. [PubMed: 7922305]
- Jang YY, Sharkis SJ. A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche. *Blood.* 2007; 110:3056–3063. [PubMed: 17595331]
- Junghans C, Rathsack S, Wacke R, Weirich V, Vogel H, Drewelow B, Mueller S, Altmann S, Freund M, Lange S. Everolimus in Combination with Cyclosporin A as Pre- and Posttransplantation Immunosuppressive Therapy in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation.* 2012; 18:1061–1068. [PubMed: 22182476]
- Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Cell biology of ischemia/reperfusion injury. *Int Rev Cell Mol Biol.* 2012; 298:229–317. [PubMed: 22878108]
- Kamleh MA, Spagou K, Want EJ. Metabolic profiling in disease diagnosis, toxicology and personalized healthcare. *Curr Pharm Biotechnol.* 2011; 12:976–995. [PubMed: 21466462]
- Kikuchi T, Mori T, Yamane A, Kato J, Kohashi S, Okamoto S. Variable magnitude of drug interaction between oral voriconazole and cyclosporine A in recipients of allogeneic hematopoietic stem cell transplantation. *Clin Transplant.* 2012; 26:E544–E548. [PubMed: 23061764]
- Kim JS, He L, Qian T, Lemasters JJ. Role of the mitochondrial permeability transition in apoptotic and necrotic death after ischemia/reperfusion injury to hepatocytes. *Curr Mol Med.* 2003; 3:527–535. [PubMed: 14527084]

- Lengner, et al. Derivation of pre-X inactivation human embryonic stem cells under physiological oxygen concentrations. *Cell*. 2010; 141:872–883. [PubMed: 20471072]
- Lewandowski D, Barroca V, Ducongé F, Bayer J, Van Nhieu JT, Pestourie C, Fouchet P, Tavitian B, Roméo PH. In vivo cellular imaging pinpoints the role of reactive oxygen species in the early steps of adult hematopoietic reconstitution. *Blood*. 2010; 115:443–452. [PubMed: 19797522]
- Lim SY, Hausenloy DJ, Arjun S, Price AN, Davidson SM, Lythgoe MF, Yellon DM. Mitochondrial cyclophilin-D as a potential therapeutic target for post-myocardial infarction heart failure. *J Cell Mol Med*. 2010
- Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. *Cell*. 1991; 66:807–815. [PubMed: 1715244]
- Lu L, Broxmeyer HE. Comparative influences of phytohemagglutinin-stimulated leukocyte conditioned medium, hemin, prostaglandin E, and low oxygen tension on colony formation by erythroid progenitor cells in normal human bone marrow. *Exp Hematol*. 1985; 13:989–993. [PubMed: 4054250]
- McGuinness O, Yafei N, Costi A, Crompton M. The presence of two classes of high-affinity cyclosporin A binding sites in mitochondria. Evidence that the minor component is involved in the opening of an inner-membrane Ca(2+)-dependent pore. *Eur J Biochem*. 1990; 194:671–679. [PubMed: 2176603]
- Mantel C, Guo Y, Lee MR, Kim MK, Han MK, Shibayama H, Fukuda S, Yoder MC, Pelus LM, Kim KS, Broxmeyer HE. Checkpoint-apoptosis uncoupling in human and mouse embryonic stem cells: a source of karyotypic instability. *Blood*. 2007; 109:4518–4527. [PubMed: 17289813]
- Mantel C, Broxmeyer HE. Sirtuin 1, stem cells, aging, and stem cell aging. *Curr Opin Hematol*. 2008; 15:326–331. [PubMed: 18536570]
- Mantel C, Messina-Graham S, Broxmeyer HE. Upregulation of nascent mitochondrial biogenesis in mouse hematopoietic stem cells parallels upregulation of CD34 and loss of pluripotency: a potential strategy for reducing oxidative risk in stem cells. *Cell Cycle*. 2010; 9:2008–2017. [PubMed: 20495374]
- Mantel C, Messina-Graham SV, Broxmeyer HE. Superoxide flashes, reactive oxygen species, and the mitochondrial permeability transition pore: potential implications for hematopoietic stem cell function. *Curr Opin Hematol*. 2011; 18:208–213. [PubMed: 21537169]
- Mantel C, Messina-Graham S, Moh A, Cooper S, Hango G, Fu XY, Broxmeyer HE. Mouse hematopoietic cell-targeted STAT3 deletion: stem/progenitor cell defects, mitochondrial dysfunction, ROS overproduction, and a rapid aging-like phenotype. *Blood*. 2012; 120:2589–2599. [PubMed: 22665934]
- Millman JR, Tan JH, Colton CK. The effects of low oxygen on self-renewal and differentiation of embryonic stem cells. *Curr Opin Organ Transplant*. 2009; 14:694–700. [PubMed: 19779343]
- Mohyeldin A, Garzón-Muvdi T, Quiñones-Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. *Cell Stem Cell*. 2010; 7:150–161. [PubMed: 20682444]
- Morrison SJ, Scadden DT. The bone marrow niche for haematopoietic stem cells. *Nature*. 2014; 505:327–334. [PubMed: 24429631]
- Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, Yamagata H, Inohara H, Kubo T, Tsujimoto Y. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. *Nature*. 2005; 434:652–658. [PubMed: 15800626]
- Nicolli A, Basso E, Petronilli V, Wenger RM, Bernardi P. Interactions of cyclophilin with the mitochondrial inner membrane and regulation of the permeability transition pore, and cyclosporin A-sensitive channel. *J Biol Chem*. 1996; 271:2185–2192. [PubMed: 8567677]
- Nii T, Marumoto T, Tani K. Roles of p53 in Various Biological Aspects of Hematopoietic Stem Cells. *Journal of Biomedicine and Biotechnology*. 2012; 2012:1–10. [PubMed: 21836813]
- Nombela-Arrieta C, Pivarnik G, Winkel B, Canty KJ, Harley B, Mahoney JE, Park SY, Lu J, Protopopov A, Silberstein LE. Quantitative imaging of haematopoietic stem and progenitor cell localization and hypoxic status in the bone marrow microenvironment. *Nat Cell Biol*. 2013; 15:533–543. [PubMed: 23624405]

- Notta F, Doulatov S, Laurenti E, Poepl A, Jurisica I, Dick JE. Isolation of Single Human Hematopoietic Stem Cells Capable of Long-Term Multilineage Engraftment. *Science*. 2011; 333:218–221. [PubMed: 21737740]
- Oguro H, Ding L, Morrison SJ. SLAM family markers resolve functionally distinct subpopulations of hematopoietic stem cells and multipotent progenitors. *Cell Stem Cell*. 2013; 13:102–116. [PubMed: 23827712]
- Perrelli MG. Ischemia/reperfusion injury and cardioprotective mechanisms: Role of mitochondria and reactive oxygen species. *Wjc*. 2011; 3:186–200. [PubMed: 21772945]
- Rossi L, Lin KK, Boles NC, Yang L, King KY, Jeong M, Mayle A, Goodell MA. Less Is More: Unveiling the Functional Core of Hematopoietic Stem Cells through Knockout Mice. *Cell Stem Cell*. 2012; 11:302–317. [PubMed: 22958929]
- Sattler M, Winkler T, Verma S, Byrne CH, Shrikhande G, Salgia R, Griffin JD. Hematopoietic growth factors signal through the formation of reactive oxygen species. *Blood*. 1999; 93:2928–2935. [PubMed: 10216087]
- Schinzel AC, Takeuchi O, Huang Z, Fisher JK, Zhou Z, Rubens J, Hetz C, Danial NN, Moskowitz MA, Korsmeyer SJ. Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia. *Proc Natl Acad Sci U S A*. 2005; 102:12005–12010. [PubMed: 16103352]
- Sjostedt S, Rooth G, Caligara F. The oxygen tension of the blood in the umbilical cord and the intervillous space. *Archives of Disease in Childhood*. 1960; 35:529–533. [PubMed: 21032372]
- Smith S, Broxmeyer HE. The influence of oxygen tension on the long-term growth in vitro of haematopoietic progenitor cells from human cord blood. *Br J Haematol*. 1986; 63:29–34. [PubMed: 3707863]
- Spencer JA, Ferraro F, Roussakis E, Klein A, Wu J, Runnels JM, Zaher W, Mortensen LJ, Alt C, Turcotte R, Yusuf R, Cote D, Vinogradov SA, Scadden DT, Lin CP. Direct measurement of local oxygen concentration in the bone marrow of live animals. *Nature*. 2014; 508:269–273. [PubMed: 24590072]
- Speth JM, Hoggatt J, Singh P, Pelus LM. Pharmacologic increase in HIF1 α enhances hematopoietic stem and progenitor homing and engraftment. *Blood*. 2014; 123:203–207. [PubMed: 24167196]
- Suda T, Takubo K, Semenza GL. Metabolic Regulation of Hematopoietic Stem Cells in the Hypoxic Niche. *Cell Stem Cell*. 2011; 9:298–310. [PubMed: 21982230]
- Sudo K, Ema H, Morita Y, Nakauchi H. Age-associated characteristics of murine hematopoietic stem cells. *J Exp Med*. 2000; 192:1273–1280. [PubMed: 11067876]
- Tanveer A, Virji S, Andreeva L, Totty NF, Hsuan JJ, Ward JM, Crompton M. Involvement of cyclophilin D in the activation of a mitochondrial pore by Ca²⁺ and oxidant stress. *Eur J Biochem*. 1996; 238:166–172. [PubMed: 8665934]
- Tothova Z, Gilliland DG. A Radical Bailout Strategy for Cancer Stem Cells. *Cell Stem Cell*. 2009; 4:196–197. [PubMed: 19265655]
- Vaseva AV, Marchenko ND, Ji K, Tsrirka SE, Holzmann S, Moll UM. p53 Opens the Mitochondrial Permeability Transition Pore to Trigger Necrosis. *Cell*. 2012; 149:1536–1548. [PubMed: 22726440]
- Vemula S, Shi J, Mali RS, Ma P, Liu Y, Hanneman P, Koehler KR, Hashino E, Wei L, Kapur R. ROCK1 functions as a critical regulator of stress erythropoiesis and survival by regulating p53. *Blood*. 2012; 120:2868–2878. [PubMed: 22889758]
- Wood SL, Westbrook JA, Brown JE. Omic-profiling in breast cancer metastasis to bone: implications for mechanisms, biomarkers and treatment. *Cancer Treat Rev*. 2014; 40:139–152. [PubMed: 23958309]
- Xu X, Duan S, Yi F, Ocampo A, Liu GH, Izpisua Belmonte JC. Mitochondrial Regulation in Pluripotent Stem Cells. *Cell Metabolism*. 2013
- Yalcin S, Zhang X, Luciano JP, Mungamuri SK, Marinkovic D, Vercherat C, Sarkar A, Grisotto M, Taneja R, Ghaffari S. Foxo3 is essential for the regulation of ataxia telangiectasia mutated and oxidative stress-mediated homeostasis of hematopoietic stem cells. *J Biol Chem*. 2008; 283:25692–25705. [PubMed: 18424439]

- Zhang H, Li H, Xi HS, Li S. HIF1 is required for survival maintenance of chronic myeloid leukemia stem cells. *Blood*. 2012; 119:2595–2607. [PubMed: 22275380]
- Zhen YF, Wang GD, Zhu LQ, Tan SP, Zhang FY, Zhou XZ, Wang XD. P53 dependent mitochondrial permeability transition pore opening is required for dexamethasone-induced death of osteoblasts. *J Cell Physiol*. 2014; 229:1475–1483. [PubMed: 24615518]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Highlights

- Exposure to ambient air compromises HSC recovery from bone marrow and cord blood.
- HSC numbers are grossly underestimated because of collection in air.
- The decrease is mediated by ROS linked to *CypD-p53-MPTP* axis, *miR210*, and *hif-1 α* .
- HSC transplantation efficiency is enhanced with cells collected in Cyclosporin A




Figure 1. BM harvest and processing in hypoxia (3%O₂) or in ambient air

A) BM was harvested and processed in a hypoxic chamber (3%O₂, 5%CO₂, N₂ balance) or ambient air (~21% O₂). Ai) Flow cytometric density dot-plots are representative of 6 independent experiments. LT-HSC are defined as CD34⁺CD48⁺LSK. Aii) Relative frequency histograms. Bar indicates CD34 positive or negative staining based on isotype control antibody. Aiii) Number of LT-HSCs collected, per 10⁶ BM cells, when harvested and processed in air (A) or in the hypoxic chamber (H); mean±SE for 6 independent experiments; statistics determined by Mann-Whitney method. B) LT-HSCs, collected from BM harvested in hypoxic chamber and divided into two; one was removed from the chamber and immediately exposed to air for 60 min (H→A), the other was left in the chamber for 60 min (H→H) before further staining and processing. Chart bars are mean±SE for 3 independent experiments. C) Length of air exposure on numbers of LT-HSCs, which were collected after harvest in hypoxic chamber (zero time) and aliquots exposed to air for 30, 60, or 90 min before staining and processing (1 experiment). Logistically, it was difficult to do a time point much less than 30 min. D) Flow cytometric density dot-plots of CD34 and CD150 expression in CD48-CD41-LSK cells. With this antibody combination, LT-HSCs are defined as CD150⁺CD34⁺CD48⁺CD41⁺LSK (Oguro, et al., 2013). Density plots represent 2 similar experiments. Ei) ROS levels in LT-HSC harvested and processed in ambient air (A→A) or in hypoxia (H→H) (3 independent harvests on the same day; mean±SD). Eii) ROS levels in CD48 LSK harvested and processed in ambient air (A→A) or in hypoxia (H→H) (3 independent harvests on the same day; mean±SD). Fi) Mitochondrial Mass Activity in LT-HSC harvested and processed in ambient air (A→A) or in hypoxia (H→H) (3 independent harvests on the same day; mean±SD). Fii) % of CD48 LSK with High Mitochondrial Mass in LT-HSC harvested and processed in ambient air (A→A) or in hypoxia (H→H) (3 independent harvests on the same day; mean±SD). Gi) Number of LT-HSCs, ST-HSCs, and MPPs collected from BM harvested in hypoxic chamber and divided into two; one was removed from the chamber and immediately exposed to air for 60 min (H→A), the other was left in the chamber for 60 min (H→H) before further staining and processing. Chart bars are mean±SE for 3 independent experiments. Hi) Colony forming units (CFU-GM, BFU-E, CFU-GEMM) and % in S-Phase in CFU-GM, BFU-E, and CFU-GEMM colonies. Chart bars are mean±SE for 3 independent experiments. Ii) Number of LT-HSCs recovered from BM harvested in hypoxic chamber and divided into two; one was removed from the chamber and immediately exposed to air for 60 min (H→A), the other was left in the chamber for 60 min (H→H) before further staining and processing. Chart bars are mean±SE for 3 independent experiments.

ROS levels in CD48⁻LSK; mean±SD for 3 independent experiments (1 mouse per collection per experiment on different days). Fi) Mitochondrial activities, measured by Mitotracker Green FM mean fluorescent intensity in CD48⁻LSK BM cells collected and processed in ambient air (A→A) or hypoxia (H→H); mean±SD for 3 independent experiments. Fii) Percentage of CD48⁻LSK cells with hyperpolarized mitochondrial membrane potential using JC-1 probe in BM collected and processed in ambient air or hypoxia; mean±SD for 3 independent experiments. G) Numbers of LT-HSC, Short-term HSC (ST-HSC; CD34⁺CD41⁻CD48⁻LSK), or multi-potent progenitors (MPP; CD48⁻Lin⁻Sca1⁻c-kit⁺); mean ±SD for 6 independent experiments (one mouse per experiment each harvested, processed, and analyzed on different days). H) Absolute numbers per femur (upper graphs) and cycling status (% in S-phase as determined by high specific activity tritiated thymidine kill assay; lower graphs) of HPC for BM cells collected and processed in hypoxia (H→H), or collected under hypoxia and placed in air for 60 min. (H → A) and then cultured in hypoxia (5% O₂). Mean ±SE for 3 mice each from 1 experiment. *p<0.05; **p<0.001. Results were reproduced in 4 additional experiments with 3 mice/group each. Ii) Representative flow cytometric contour plots of human LT-HSC (Lin⁻CD34⁺CD38⁻CD45RA⁻CD90⁺CD49f⁺ as per Notta et al., 2011) from CB collected under hypoxic conditions with half left in hypoxia for processing (H→H) and half left in air for 60 min. (H→A). Iii) Number of phenotyped human CB-derived HSC per 10⁶ total cells; mean ± SD for 4 independent CB harvests. See also Figure S1.




Figure 2. Competitive mouse HSC repopulation, HSC homing, Apoptosis, and CXCR4 expression

A) Competitive HSC engraftment. Donor cells were CD45.2⁺, competitors were CD45.1⁺ (competitor cells all collected in air and injected either in hypoxia or air immediately after donor cells were injected), and infused into 950 cGy irradiated dual CD45.2⁺/CD45.1⁺ F1 recipients at 150K donor and 150K competitor cells. Ai) BM cells were harvested in hypoxia and cells split so that half were processed and injected in hypoxia, and half subjected to air for 60 min. prior to processing and injecting in air. Mean ± SE of CD45.2⁺ (donor cell) chimerism (1 experiment) for numbers of mice evaluated. Open circles (hypoxia (H)→Air (A)) and closed circles (H→H). Aii) Combined results of 2-3 separate engrafting studies as noted in text. Aiii) CRUs calculated from LDA as per Antonchuk, et. al., 2002 (n=3-4 mice per group at each cell concentration infused for each of two experiments) for month 3 peripheral blood and month 7/8 for BM. P value is based on Poisson statistics. B) Homing of cells collected in hypoxia, and then left to be processed and injected under hypoxia (H→H for input), or collected under hypoxia and then exposed to room air for 60 minutes before processing and injecting cells in air (H→A for input). Cells were analyzed 24 hours after injection by removing 2 femurs plus 2 tibias from 10 mice under hypoxia and splitting the cells into two, one half which was left at hypoxia for staining and assessment (H→H for output) and one half placed into air for 60 min. for staining and assessment

(H→A for output). Lin- BM cells were injected and % LSK cells homed (output to input LSK) showed no significant differences in any of the groups by ANOVA analysis Ci) Representative relative frequency histograms of CXCR4 surface staining intensity in LT-HSCs. Cii) Mean fluorescence staining intensity of 4 BM harvests (mean \pm SD). D) Flow cytometric assessment of apoptosis using antibody to activated caspase-3. Data represent 2 similar experiments.

See also Figure S2.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 3. MPTP in EPHOSS: effects of cyclosporine A

A) Effects of BM harvest in air in presence of 50 μ g/ml cyclosporine A (CSA-harvest) or DMSO control on CD34 expression levels in CD48-LSK cells. For CSA group, mice used for cell collection were injected with CSA (Experimental Procedures). Mice for control group were injected with control medium. Representative flow cytometric density dot-plot for 3 independent harvests. LT-HSCs are noted in circles. B) Dose-response of CSA on LT-HSC collection (N=1 expt). Ci) Relative frequency histogram representative of 3 independent harvests in DMSO or 50 μ g/ml CSA. Cii) Average LT-HSCs collected after DMSO or CSA-harvest (3 independent experiments; mean \pm SD). Ciii) Effect of time of air exposure on BM harvested in the presence of either DMSO or CSA (1 experiment). D) Effects of CSA or DMSO harvest on GM-CSF plus SCF-induced CFU-GM colony formation (mean \pm SD from 6 mice each in a total of 2 experiments). Effects of FK506- (E) or carboxyatractylate- (CAT-) (F) harvests shown as a relative frequency histogram from flow cytometric data. Data in E and F are representative of 2 independent experiments each with similar results. Bar charts are quantitation (mean \pm range) for 2 experiments. G) Effect of DMSO-, CSA-, or CAT-harvest on ROS levels in CD48-LSK cells (mean of 2 independent experiments \pm range). Hi) Effect of CSA-harvest, compared to DMSO (control; C)-harvest, on HSC engraftment in competitive repopulation transplant assay (mean % CD45.2⁺ donor cell chimerism \pm SE for numbers of mice shown at each point. Results for months 1-4, and 8 for primary mice are for 2 experiments, while that at 1,3 months for secondary mice are for 1 experiment. Hii) CRUs calculated by LDA analysis respectively at 3 months for peripheral blood (PB) and at 8 months for BM (n=3-5 mice per group at each cell concentration infused for each of two experiments). P value is based on Poisson statistics. See also Figures S3 and S4.




Figure 4. Effect of human CB CSA and mouse BM cyclophilin D (*CypD*)^{-/-} collections

A) Effect of CSA collection on CB CD34⁺ cells, LT-HSCs, and MPPs. Results are from 5 different CB collections. B) CRUs calculated from LDA (n=3-5 mice per group at each cell concentration for each of 2 separate CB collections. Bi) Combined results of 2 expts at 2 months for PB. Bii) Results of one of the CB collections at 3.5 months for BM. Biii) Results of the other CB collection at 4.5 months for BM (Bii and Biii results for BM were not combined as the percent chimerism for both was largely different precluding averaging the results for LDA). Ci) Effect of *CypD* gene deletion on phenotyped LT-HSC recovery when BM is harvested in air (N=7 experiments). Cii) ROS levels in LT-HSC cells harvested from 5 of the 7 different experiments shown in Ci. D) Recovery of multi-cytokine-stimulated CFU-GM, BFU-E, and CFU-GEMM (Average of 6 WT and 10 *CypD*^{-/-} mice in a total of 2 experiments expressed as mean ±SE). E) GM-CSF plus SCF-induced CFU-GM colony formation (mean ± SE) in BM from same animals as in D. F) Percent PB chimerism of *CypD*^{-/-} BM cell engraftment at limiting dilution analysis for months 1-3 in PB and at 4.5 months in BM (4-5 mice/group at each cell concentration for 1 expt.). Fii) CRUs as calculated for month 2 and 3 PB and month 4.5 BM by LDA for *CypD*^{-/-} BM cell engraftment.

See also Figures S4 and S5.




Figure 5. Effect of *p53*, *miR210* or *hif-1 α* gene deletion

A) Effect of *p53* gene deletion on hypoxic (H \rightarrow H) and air (H \rightarrow A) BM harvest on phenotyped LT-HSC recovery for independent BM harvests from six *p53*^{-/-} and three littermate control wild type (WT) mice. BM from each mouse was harvested and maintained in the hypoxic chamber for 60 min before staining and fixation (H \rightarrow H) or was exposed to air for 60 min before staining and fixation (H \rightarrow A). Mean LT-HSC per 10⁶ nucleated BM cells \pm SD for each group. B) Effect of *p53* gene deletion on multi-cytokine stimulated progenitor cell recovery (left) or cell cycle status (right; high specific activity tritiated thymidine kill assay). BM was from the same animals harvested in E and cells were cultured in hypoxia (5%O₂). C) Phenotyped LT-HSC, ST-HSC, and MPP, recovery for *miR210*^{-/-} (i), or *hif-1 α* ^{-/-} (ii) BM. Cells from one femur were collected and processed in air (A) and cells from the contralateral femur were collected and processed in hypoxia (H). One of two experiments with similar results for (i), and one experiment for (ii). D) HPC recovery from *miR210*^{-/-} (i) or *hif-1 α* ^{-/-} (ii) BM harvested and processed in air (A), or hypoxia (H), and cultured in hypoxia (5%O₂). 1 of 3 reproducible experiments with 3 mice/group for each experiment for the *miR210*^{-/-} mice in which one femur was collected in air and the contralateral femur collected in hypoxia, with one of the other two experiments done in a similar manner, and one experiment done with collection in hypoxia and processing in air

vs. collection and processing in hypoxia. 1 of 2 reproducible experiments for *hif-1 α* *-/-* mice with harvest in air vs. hypoxia. a=significant ($p<0.01$) compared to WT A control, b=not significant ($p>0.05$) compared to *hif-1 α* *-/-* or *miR210* *-/-*.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript